Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT05743036	TitleZN-c3 in Adult Participants With BRAF mutant Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2023-02-24	Location California, United States Kansas, United States Texas, United States Australia Germany Hungary Italy Poland Spain	Prior IO Allowed Yes	CRC-directed Yes	Status Terminated	Drugs cetuximab, encorafenib, ZN-c3	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03984578	TitleWindow of Opportunity Study in Colorectal Cancer	Phase Phase 2	Date Added 2019-06-13	Location Singapore	Prior IO Allowed No	CRC-directed Yes	Status Completed	Drugs Capecitabine/ 5-FU, CapeOX, Pembrolizumab, Eloxatin, Keytruda	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05771181	TitleVitamin E Combined With Fruquintinib and Tislelizumab in Microsatellite Stabilized Metastatic Colorectal Cancer Patients	Phase Phase 2	Date Added 2023-03-16	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Fruquintinib, Tislelizumab, Vitamin E	Tags MSS/ MMRp
NCT ID NCT03290937	TitleUtomilumab, Cetuximab, and Irinotecan Hydrochloride in Treating Patients With Metastatic Colorectal Cancer	Phase Phase 1	Date Added 2017-09-25	Location Texas, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs cetuximab, Irinotecan Hydrochloride, Utomilumab	Tags MSS/ MMRp
NCT ID NCT05976906	TitleUniversal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid Tumors	Phase Phase 1	Date Added 2023-08-04	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04483219	TitleTyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.	Phase Phase 2	Date Added 2020-07-23	Location China	Prior IO Allowed Yes	CRC-directed Yes	Status Unknown status	Drugs TKI ± anti-PD-1 antibody	Tags MSS/ MMRp
NCT ID NCT04589845	TitleTumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study	Phase Phase 2	Date Added 2020-10-19	Location Alabama, United States Arizona, United States California, United States Colorado, United States Delaware, United States Florida, United States Georgia, United States Idaho, United States Illinois, United States Indiana, United States Maine, United States Maryland, United States Michigan, United States Minnesota, United States Missouri, United States Montana, United States Nebraska, United States Nevada, United States New Hampshire, United States New Jersey, United States New Mexico, United States New York, United States Ohio, United States Oregon, United States Pennsylvania, United States South Carolina, United States Tennessee, United States Texas, United States Washington, United States Wisconsin, United States Australia Belgium Brazil Canada China Denmark France Germany Hong Kong Israel Italy Japan New Zealand Poland Portugal Puerto Rico Singapore South Africa South Korea Spain Switzerland Taiwan United Kingdom	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs Alectinib, Atezolizumab, Belvarafenib, Entrectinib, Idasanutlin, Inavolisib, Ipatasertib, Pralsetinib, Trastuzumab emtansine	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT02856425	TitleTrial Of Pembrolizumab And Nintedanib	Phase Phase 1	Date Added 2016-08-04	Location France	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs Nintedanib, Pembrolizumab, Keytruda, Ofev, Vargatef	Tags MSS/ MMRp
NCT ID NCT03921684	TitleTrial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients	Phase Phase 2	Date Added 2019-04-19	Location Israel	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs capecitabine, mFOLFOX6, Nivolumab	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT04003792	TitleTreatment With Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic FOLFIRI Chemotherapy and Bevacuzimab in Patients With Liver-only Colorectal Liver Metastases (CRLM): Conversion to Complete Resection in Patients With Initially Inoperable Liver-only CRLM.	Phase Phase 2	Date Added 2019-07-01	Location Israel	Prior IO Allowed Yes	CRC-directed Yes	Status Recruiting	Drugs Bevacizumab, FOLFIRI Protocol, oxaliplatin	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 1 to 10 of 299 entries